Home-based digital platform delivering sequential therapy for people with glioma
Official title: MC240703 Neuro-Oncology Anywhere: Glioma Home-Based Sequential Therapy (GHoST) Protocol
Run by Mayo Clinic · NCT07074756 · Data updated 2026-11-12
This program will test a mobile app that helps deliver and remotely monitor home-based systemic therapy for adults with newly diagnosed or recurrent glioma.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 202 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | bevacizumab, radiation, chemotherapy |
| Locations | 2 sites (Jacksonville, Florida and 1 other locations) |
| Status | Recruiting |
| Started | September 12, 2025 |
| Main results expected | August 31, 2028 |
| Study ends | August 31, 2028 |
| Registry record updated | August 10, 2026 |
| Trial ID | NCT07074756 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with newly diagnosed or recurrent glioma planning at least six months of systemic therapy, with ECOG performance status 0–2 (KPS ≥60) and an expected survival of six months or more, are the ideal candidates.
✕Probably not a fit
Patients who are pregnant or nursing, incarcerated, lack capacity for informed consent, cannot use or access the digital platform, or who have very limited life expectancy or poor functional status are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The GHoST platform uses a mobile application to deliver and remotely monitor sequential systemic therapies for adults with newly diagnosed or recurrent glioma. Patients receive treatment at home while clinicians track adherence, symptoms, and safety data through the platform alongside scheduled imaging and neurologic exams. The primary goal is to determine feasibility of remote chemotherapy management, with secondary endpoints including adherence, progression-free survival, objective response rate, and safety. Exploratory analyses will measure patient satisfaction and examine how adherence and access differ by socioeconomic factors.
Why it matters
Potential benefit: If successful, the platform could expand access to neuro-oncology specialists, enable more patients to receive and monitor systemic therapy at home, and increase participation in clinical research.
How similar studies have gone: Telemedicine and remote monitoring have improved oncology care delivery and trial participation in other cancers, but applying a dedicated home-based sequential chemotherapy platform specifically for glioma is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of glioma and intention to treat with either new or ongoing systemic therapy for at least 6 months. * NOTE: Patient may be enrolled following completion of surgery and/or radiation therapy for newly diagnosed or recurrent tumor. * NOTE: Any number of prior recurrences is permitted * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, AND Karnofsky performance status (KPS) of ≥ 60 * Expected survival ≥ 6 months in the opinion of treatment team * Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations * Negative pregnancy test ≤ 8 days prior to registration for persons of childbearing potential only * Exception: Not required if patient is already on treatment. May be obtained prior to next treatment as needed per clinical care * Provide written informed consent * Ability to complete assessments and questionnaires by themselves or with assistance * SUBSTUDY 1: Enrolled in GHoST Master Protocol per eligibility criteria of the master study and clinically appropriate to proceed with bevacizumab treatment at the discretion of the treating physician * SUBSTUDY 1: Diagnosis of recurrent glioblastoma and intention to treat with bevacizumab * NOTE: Any number of prior recurrences is permitted * NOTE: Prior limited use of bevacizumab for radiation necrosis/treatment related edema is permitted. Prior use should not exceed four infusions with the last dose administered ≥ 4 weeks prior to enrollment in this substudy * SUBSTUDY 1: Willing and able to adhere to the substudy for the duration of the substudy including undergoing treatment, and attending scheduled visits, and examinations * SUBSTUDY 1: Negative pregnancy test ≤ 8 days prior to registration for persons of childbearing potential only * SUBSTUDY 1: Provide written informed consent * SUBSTUDY 1: Ability to complete assessments and questionnaires by themselves or with assistance Exclusion Criteria: * Pregnant or nursing, imprisoned, or lacking capacity for understanding * Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings * SUBSTUDY 1: Pregnant or nursing, imprisoned, or lacking capacity for understanding * SUBSTUDY 1: Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings
Where it's running
-
Mayo Clinic in Florida
Jacksonville, Florida, United States Recruiting -
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Ugur T. Sener, MD — Mayo Clinic in Rochester
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sitagliptin plus bevacizumab for recurrent grade 4 glioma
This study tests whether adding sitagliptin to bevacizumab can help people whose recurrent glioblastoma or other grade 4 gliomas respond to treatment and to find a safe dose when used with bevacizumab.
-
LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma
This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.
-
Proton pulsed reduced-dose-rate radiotherapy for recurrent high-grade glioma
This trial tests whether a special proton radiation method called PRDR helps people whose fast-growing glioma has come back after prior radiation.
-
Re-irradiation for recurrent glioblastoma
This study is testing a new way to safely give radiation treatment again to adults with recurring glioblastoma to see if it can improve their options after their tumors come back.
-
Using CARv3-TEAM-E T Cells to treat glioblastoma
This study is testing the best dose of a new type of immune cell treatment for people with glioblastoma, a serious brain cancer, to see how safe and effective it is.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.